Put Options

18 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q1 2024

Apr 19, 2024

SELL
$63.75 - $108.06 $89,250 - $151,284
-1,400 Reduced 12.17%
10,100 $8,000
Q4 2023

Jan 18, 2024

BUY
$26.88 - $83.49 $150,528 - $467,544
5,600 Added 94.92%
11,500 $6,000
Q3 2023

Nov 07, 2023

BUY
$29.46 - $36.61 $170,868 - $212,338
5,800 Added 5800.0%
5,900 $30,000
Q2 2023

Jul 18, 2023

BUY
$32.62 - $40.75 $3,261 - $4,075
100 New
100 $0
Q4 2022

Feb 07, 2023

BUY
$35.77 - $51.11 $103,733 - $148,219
2,900 Added 966.67%
3,200 $2,000
Q2 2022

Aug 04, 2022

SELL
$33.93 - $48.92 $101,790 - $146,760
-3,000 Reduced 90.91%
300 $1,000
Q1 2022

Apr 14, 2022

BUY
$29.74 - $46.0 $92,194 - $142,600
3,100 Added 1550.0%
3,300 $17,000
Q4 2021

Jan 18, 2022

SELL
$34.35 - $46.38 $199,230 - $269,004
-5,800 Reduced 96.67%
200 $0
Q3 2021

Oct 26, 2021

SELL
$18.54 - $35.74 $100,116 - $192,996
-5,400 Reduced 47.37%
6,000 $10,000
Q4 2020

Jan 21, 2021

SELL
$15.26 - $28.61 $7,630 - $14,305
-500 Reduced 4.2%
11,400 $12,000
Q3 2020

Oct 27, 2020

BUY
$20.58 - $28.96 $244,901 - $344,624
11,900 New
11,900 $75,000
Q1 2019

May 10, 2019

SELL
$5.95 - $10.19 $50,575 - $86,615
-8,500 Closed
0 $0
Q4 2018

Feb 05, 2019

BUY
$5.91 - $9.29 $50,235 - $78,965
8,500 New
8,500 $34,000
Q3 2018

Nov 07, 2018

SELL
$6.4 - $9.85 $1,280 - $1,970
-200 Closed
0 $0
Q2 2018

Aug 10, 2018

SELL
$6.9 - $9.9 $7,590 - $10,890
-1,100 Reduced 84.62%
200 $0
Q1 2018

May 11, 2018

SELL
$7.2 - $10.05 $36,720 - $51,255
-5,100 Reduced 79.69%
1,300 $6,000
Q4 2017

Jan 17, 2018

SELL
$7.25 - $15.65 $312,475 - $674,515
-43,100 Reduced 87.07%
6,400 $26,000
Q3 2017

Oct 17, 2017

BUY
$12.0 - $15.0 $594,000 - $742,500
49,500
49,500 $18,000

Others Institutions Holding CYTK

About CYTOKINETICS INC


  • Ticker CYTK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,144,096
  • Market Cap $4.57B
  • Description
  • Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...
More about CYTK
Track This Portfolio

Track Cutler Group LP Portfolio

Follow Cutler Group LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

News

Stay updated on Cutler Group LP with notifications on news.